Tocilizumab-Associated Ventricular Tachycardia Case in a COVID-19 Patient
Balıkesir Medical Journal · 2022
DOI: 10.33716/bmedj.1053956 ↗Kurz gefasst
Fachartikel in der Zeitschrift Balıkesir Medical Journal, 2022. Verfasst von Deniz İNCAMAN und 1 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben. Gefördert von: yok.
Abstract (Originalsprache)
COVID-19 (Coronavirus Disease-2019) which is dependent on SARS-CoV-2 (Severe Acute Respiratory Syndrome) virus started as a pandemic which affected every sphere of life. The disease progresses more heavily and higher mortality is observed in the COVID-19 patients who had cardiovascular disease before or cardiovascular risk factors (smoking habit, male gender, old age, obesity, diabetes, hyperlipidemia and hypertension). Both COVID-19 disease and the drugs used during treatment lead to cardiac arrhythmia. In this study, a case that was followed up in intensive care unit because of COVID-19 disease and had ventricular tachycardia following Tocilizumab treatment was presented.
Förderung
- yok
Zitieren
APA
İNCAMAN, D., & ÇINAR, M. (2022). Tocilizumab-Associated Ventricular Tachycardia Case in a COVID-19 Patient. Balıkesir Medical Journal. https://doi.org/10.33716/bmedj.1053956
Vancouver
İNCAMAN D, ÇINAR M. Tocilizumab-Associated Ventricular Tachycardia Case in a COVID-19 Patient. Balıkesir Medical Journal. 2022. doi:10.33716/bmedj.1053956
BibTeX
@article{NCAMAN2022,
author = {İNCAMAN, Deniz and ÇINAR, Mahmut},
title = {Tocilizumab-Associated Ventricular Tachycardia Case in a COVID-19 Patient},
journal = {Balıkesir Medical Journal},
year = {2022},
doi = {10.33716/bmedj.1053956}
}
EUVIMED